It may give the company and the stock a needed lift over the next while but Pfizer\u2019s (Pfizer Stock Quote, Chart, News NYSE:PFE) COVID-19 vaccine shouldn\u2019t be attracting your investment dollars for the long haul, says portfolio manager Jamie Murray, who has another, higher-growth pharma stock in mind. Pfizer last week announced that a Phase 3 trial of its coronavirus vaccine has proven 95-per-cent effective in preventing infections, with no serious safety concerns, an announcement that came just a week after an initial look at the data showed the vaccine to better-than 90-per-cent effective. \u201cEfficacy was consistent across age, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94 per cent,\u201d said Pfizer and its German partner BioNTech said in a statement. The news shot up Pfizer\u2019s share price momentarily, but that was enough for Murray, who promptly sold Pfizer and moved on to AstraZeneca (AstraZeneca Stock Quote, Chart, News NASDAQ:AZN), another company in the hunt for a COVID-19 vaccine. \u201cWe actually sold our Pfizer shares that we held our global growth fund about two weeks ago on the day that they put up the vaccine news,\u201d said Murray, head of research for the Murray Wealth Group, who spoke to BNN Bloomberg on Monday. \u201cIt was a name that we wee already looking at trimming or selling and then when we got that the vaccine news and saw the shares were up 15 per cent we decided to exit the position.\u201d Murray says Pfizer\u2019s growth prospects aren\u2019t looking as good as they should right now to attract investors. \u201cThey\u2019re going through the spin-off of their generic business called Upjohn into a company with Mylan so there are a lot of things going on with Pfizer that we\u2019re looking at, but we don\u2019t think the vaccine is going to be a long-term profit driver. It\u2019s more of a short-term effect on their financials \u2014 it\u2019ll be a nice little boost for the next two years and then really go away.\u201d \u201cBut the big reason why we moved on from Pfizer was they had a big miss with their oncology program back in June that really impacted the long-term growth rate of the company going forward, so we were looking for that time to move on and we actually redeployed the funds into another drug company called AstraZeneca.\u201d Pfizer, whose share price has headed lower over the past couple of years and is currently down seven per cent for 2020, delivered mixed results in its latest quarter at the end of October, with revenues down four per cent year-over-year to $12.13 billion and adjusted diluted EPS down three per cent to $0.72 per share. Analysts had been expecting $12.32 billion and $0.71 per share, respectively. (All figures in US dollars.) The company remained upbeat on its prospects, pointing to gains of three per cent year-over-year over the third quarter in its Biopharma segment, along with Pfizer\u2019s efforts on the COVID vaccine front. \u201cIn the first nine months of the year, our Biopharma business grew seven per cent operationally, despite a COVID-19-related negative impact of approximately two per cent, driven by the strong performance of many of our key brands,\u201d said CFO Frank D\u2019Amelio in a press release. \u201cThis performance adds to our confidence in our ability to achieve our expectation of at least a six per cent compound annual revenue growth rate through 2025 for New Pfizer.\u201d AstraZeneca announced on Monday that its late-stage COVID vaccine trials in conjunction with Oxford University have so far proven up to 90-per-cent effective in preventing the disease, making it three drug companies \u2014 along with Pfizer and Moderna \u2014 to announce trial results in the past two weeks. On AstraZeneca\u2019s promise, Murray said, \u201cAstraZeneca has got a little bit higher growth rate growing revenue about ten per cent a year for the next few years. And it has a really nice pipeline of new drugs as well, so that\u2019s where we\u2019d be looking to put new money.\u201d \u201cWe\u2019ve seen stock really rally from the $32-$33 range up to $37, $38 on the vaccine news,\u201d Murray said. \u201cPfizer is a $225-billion company so there\u2019s lots of the vaccine news that has been priced into shares.\u201d Filling out the picture on Pfizer, analyst Louise Chen of Cantor Fitzgerald delivered a report to clients on November 2, saying that a successful coronavirus vaccine, once deployed worldwide, could represent a recurring revenue stream for Pfizer worth about $5 per share. From a less rosy perspective, Chen said if the vaccine is more of a one-time product for Pfizer, it would be worth $2 per share and, if the vaccine doesn\u2019t make it to market at all, that would be a downside of about $4 per share. \u201cThis is because the FactSet consensus already has $1.4 billion of sales for PFE's COVID-19 vaccine in 2020, $8.7 billion in 2021 and ~$2.1 billion annually, thereafter,\u201d Chen said. The analyst gave a rating of \u201cOverweight\u201d to PFE with a target price of $53 per share, which at press time represented a projected 12-month return of 49 per cent.